AGA2118

Phase 2Small molecule

AAngitia Biopharmaceuticals

AGA2118 is one of 15 small molecule programs targeting Postmenopausal Women. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Postmenopausal WomenActive, not recruiting

Postmenopausal WomenPhase 2

Active, not recruiting

Competition

Competitive Landscape

17 competitors in Postmenopausal Women

#DrugCompanyPhaseTrials

Afinitor

Novartis

Phase 2

4 2

Depo-Testosterone

AAzurity Pharmaceuticals

Phase 2

1 3

Cortrosyn

Novartis

Phase 1

1 4

Decadron

AAspen Global Incorporated

Phase 1

1 5

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 1

1 6

Orgalutran

OOrganon and Co

Phase 1

1 7

Phytoestrogen

CCairo University

Phase 3

1 8

Factrel

Ferring

Phase 1

1 9

AGA2118

AAngitia Biopharmaceuticals

Phase 2

2 10

Recombinant Human Luteinizing Hormone

Merck & Co.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Active, not recruiting

Postmenopausal Women

NCT06577935

Clinical

Trials by Indication[1]

Postmenopausal Women2 trials

A Trial Evaluating Efficacy of AGA2118 in PostMenopausal Women wIth Low Bone MasS (ARTEMIS)

Active, not recruiting·AAngitia Biopharmaceuticals·Phase 2·NCT06577935·379 enrolled

A First-in-Human Study Evaluating AGA2118 in Men and Postmenopausal Women

Completed·AAngitia Biopharmaceuticals·Phase 1·NCT05225857·90 enrolled

Unspecified1 trial

A Phase 1, Randomized, Open-Label, Single-Dose Study to Evaluate the Pharmacokinetics of AGA2118 in Healthy Japanese, Chinese, and Caucasian Participants

Completed·AAngitia Incorporated Limited·Phase 1·NCT07361354·28 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for AGA2118. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AGA2118 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AGA2118. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Angitia Biopharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAngitia Biopharmaceuticals

AGA2118

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Postmenopausal Women2 trials

Unspecified1 trial

References

Drug Info

Quick Facts

Related News